Reslizumab for EGPA in adults
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older (male or female).
- Have an EGPA diagnosis for at least 6 months.
- Have EGPA supported by asthma plus high eosinophils (a type of white blood cell) and at least two other EGPA features (like nerve problems, sinus issues, lung findings, heart muscle involvement, kidney inflammation, skin rash, or ANCA-positive tests).
- Use stable medicines for a set time: prednisone/prednisolone at 5 mg or more daily for at least 4 weeks, and other immune medicines at a steady dose for at least 4 weeks (if applicable).
- If you recently used cyclophosphamide (CYC), it must be stopped for a required amount of time before starting, and blood counts must meet a threshold.
- If you can become pregnant: use reliable birth control during the trial and for 4 months after, and agree to pregnancy testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
This study looks at how well benralizumab (Fasenra) works for people with EGPA, a rare disease that causes inflammation in blood vessels and can affect the lungs, skin, and nerves. By tracking people already on this treatment, researchers hope to learn more about its long-term effectiveness.
This trial tests how well mepolizumab works for people with asthma or a related condition called EGPA, and looks for markers in the blood that may predict organ damage or treatment response.
This trial tests a new medicine called SHR-1703 for people with EGPA that has come back or is hard to treat. It aims to see if the drug can help control the disease better.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.